<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: The prophylactic effect of FOLFOX regimen, a standard regimen for unresectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), was investigated in the adjuvant setting of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases with distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The study population included 116 CRC patients with synchronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> and 91 patients with metachronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> who had undergone curative operation in our hospital between 2000 and 2009 </plain></SENT>
<SENT sid="2" pm="."><plain>Clinicopathological parameters of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, postoperative chemotherapeutic regimen, recurrence rate, and relapse-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e>) were analyzed retrospectively </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: After resection of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and synchronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, 53 (84%) out of 63 patients without chemotherapy, and 38 (83%) out of 46 that received <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) alone or with leucovorin (LV) developed <z:e sem="disease" ids="C0521158" disease_type="Neoplastic Process" abbrv="">recurrent tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>By contrast, only 1 (17%) among 6 patients who underwent FOLFOX treatment showed recurrence </plain></SENT>
<SENT sid="5" pm="."><plain>The FOLFOX group exhibited significantly improved <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> as compared to the 5-FU (+ LV) or surgery-alone group (p = 0.03, p = 0.007, respectively) </plain></SENT>
<SENT sid="6" pm="."><plain>On the other hand, in patients with metachronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-relapse rate and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RFS</z:e> were not significantly influenced by post-metastasectomy therapies </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: In this retrospective analysis, the adjuvant administration of FOLFOX appeared to reduce the risk of relapse in a small group of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with synchronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Prospective randomized trials will be required to confirm the benefits of this management strategy </plain></SENT>
</text></document>